KFDA to review data exemption for combined drug registration.

Published: 2006-03-21 06:56:00

Updated: 2006-03-21 06:56:00

The KFDA said in the brief talk meeting with the pharmaceutical companies of developing a combined anti-diabetic drug that the standards required for the combined drug registration data should be wholly reviewed to an effect that 4 data including general pharmacological study data for a combined ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK